Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

25.59 -0.18 (-0.72%)
Streaming Delayed Price Updated: 10:50 AM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government... 
Via Benzinga
News headline image
Analyst Expectations For Celldex Therapeutics's Future ↗
 
Via Benzinga
News headline image
Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) ↗
CLDX stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout above the $26.20 resistance level. 
Via Chartmill
News headline image
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics ↗
 
Via Benzinga
News headline image
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Celldex Therapeutics Stock ↗
 
Via Benzinga
News headline image
5 Analysts Assess Celldex Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short ↗
Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement. 
Via Benzinga
News headline image
What Analysts Are Saying About Celldex Therapeutics Stock ↗
 
Via Benzinga
News headline image
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock ↗
 
Via Benzinga
News headline image
Analyst Expectations For Celldex Therapeutics's Future ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Are Celldex Shares Tumbling After Hours? ↗
The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress ↗
Celldex Therapeutics Q2 2025 earnings: Revenue misses estimates at $730K, but EPS beats at -$0.85. Strong cash position supports pipeline, with key barzolvolimab trials progressing. 
Via Chartmill
News headline image
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded ↗
Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks. 
Via Stocktwits
News headline image
Crude Oil Rises 6%; US Consumer Sentiment Surges In June ↗
 
Via Benzinga
News headline image
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Expectations For Celldex Therapeutics's Future ↗
 
Via Benzinga
News headline image
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
7 Analysts Have This To Say About Celldex Therapeutics ↗
 
Via Benzinga
News headline image
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors ↗
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.